Neuroimaging, genetic, clinical, and demographic predictors of treatment response in patients with social anxiety disorder

J Affect Disord. 2020 Jan 15:261:230-237. doi: 10.1016/j.jad.2019.10.027. Epub 2019 Oct 20.

Abstract

Background: Correct prediction of treatment response is a central goal of precision psychiatry. Here, we tested the predictive accuracy of a variety of pre-treatment patient characteristics, including clinical, demographic, molecular genetic, and neuroimaging markers, for treatment response in patients with social anxiety disorder (SAD).

Methods: Forty-seven SAD patients (mean±SD age 33.9 ± 9.4 years, 24 women) were randomized and commenced 9 weeks' Internet-delivered cognitive behavior therapy (CBT) combined either with the selective serotonin reuptake inhibitor (SSRI) escitalopram (20 mg daily [10 mg first week], SSRI+CBT, n = 24) or placebo (placebo+CBT, n = 23). Treatment responders were defined from the Clinical Global Impression-Improvement scale (CGI-I ≤ 2). Before treatment, patients underwent functional magnetic resonance imaging and the Multi-Source Interference Task taxing cognitive interference. Support vector machines (SVMs) were trained to separate responders from nonresponders based on pre-treatment neural reactivity in the dorsal anterior cingulate cortex (dACC), amygdala, and occipital cortex, as well as molecular genetic, demographic, and clinical data. SVM models were tested using leave-one-subject-out cross-validation.

Results: The best model separated treatment responders (n = 24) from nonresponders based on pre-treatment dACC reactivity (83% accuracy, P = 0.001). Responders had greater pre-treatment dACC reactivity than nonresponders especially in the SSRI+CBT group. No other variable was associated with clinical response or added predictive accuracy to the dACC SVM model.

Limitations: Small sample size, especially for genetic analyses. No replication or validation samples were available.

Conclusions: The findings demonstrate that treatment outcome predictions based on neural cingulate activity, at the individual level, outperform genetic, demographic, and clinical variables for medication-assisted Internet-delivered CBT, supporting the use of neuroimaging in precision psychiatry.

Keywords: CBT; Pattern recognition; Personalized medicine; SSRI; SVM; Social phobia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Amygdala / diagnostic imaging
  • Amygdala / physiopathology
  • Anxiety Disorders / diagnosis*
  • Anxiety Disorders / genetics
  • Anxiety Disorders / physiopathology
  • Anxiety Disorders / therapy*
  • Citalopram / therapeutic use
  • Cognitive Behavioral Therapy
  • Demography
  • Female
  • Gyrus Cinguli / diagnostic imaging
  • Gyrus Cinguli / physiopathology
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Neuroimaging
  • Phobia, Social / diagnosis*
  • Phobia, Social / genetics
  • Phobia, Social / physiopathology
  • Phobia, Social / therapy*
  • Selective Serotonin Reuptake Inhibitors / therapeutic use
  • Treatment Outcome

Substances

  • Serotonin Uptake Inhibitors
  • Citalopram

Associated data

  • ISRCTN/ISRCTN24929928